Advertisement

Cholinergic approaches to the treatment of progressive supranuclear palsy

  • I. Litvan
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 42)

Summary

In spite of the severe loss of cholinergic neurons in the brains of patients with progressive supranuclear palsy (PSP), marginal or null benefits are seen in clinical trials after the administration of physostigmine, a cholinesterase inhibitor, or RS-86, a cholinergic agonist. The possible role of cholinergic therapy in PSP is reevaluated.

Keywords

Progressive Supranuclear Palsy Pedunculopontine Nucleus Pseudobulbar Palsy Selective Remind Oral Physostigmine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agid Y, Javoy-Agid F, Ruberg M, Pillon B, Dubois B, Duyckaerts C, Hauw JJ, Baron JC, Scatton B (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 191–206.Google Scholar
  2. Atack JR, Litvan I, Thal LJ, May C, Rapaport SI, Chase TN (1991) Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neurol Neurosurg Psychiatry 54: 832–835.PubMedCrossRefGoogle Scholar
  3. Brandel JP, Hirsch EC, Malessa S, Duyckaerts C, Cervera P, Agid Y (1991) Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy. Neuroscience 41: 25–31.PubMedCrossRefGoogle Scholar
  4. Brown J (1958) Some test of decay theory of immediate memory. Q J Exp Psychol 39: 15–22.Google Scholar
  5. Buschke H, Altman Fuld P (1974) Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24: 1019–1025.PubMedCrossRefGoogle Scholar
  6. Duvoisin RC (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17: 124–136.PubMedCrossRefGoogle Scholar
  7. Duvoisin R (1992) Clinical diagnosis. In: Litvan I, Agid Y (eds) Progressive supranuclear palsy: clinical and research approaches. Oxford University Press, pp 15-33.Google Scholar
  8. Foster NL, Aldrich MS, Bluemlein MS, White RF, Berent S (1989) Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 39: 257–261.PubMedCrossRefGoogle Scholar
  9. Giacobini E (1991) The second generation of cholinesterase inhibitors: pharmacological aspects. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 247–262.Google Scholar
  10. Grafman J, Litvan I, Gomez C, Chase TN (1990) Frontal lobe function in progressive supranuclear palsy. Arch Neurol 47: 553–558.PubMedCrossRefGoogle Scholar
  11. Hauw JJ, Verny M, Delaere P, Cervera P, He Y, Duyckaerts C (1990) Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer’s disease and aging. Neurosci Lett 119: 182–186.PubMedCrossRefGoogle Scholar
  12. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 84: 5976–5980.PubMedCrossRefGoogle Scholar
  13. Jellinger K (1988) The pedunculopontine nucleus in Parkinson’s disease, progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 51: 540–543.PubMedCrossRefGoogle Scholar
  14. Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y (1991) Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology 41: 25–30.PubMedCrossRefGoogle Scholar
  15. Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18: 530–536.PubMedCrossRefGoogle Scholar
  16. Kertzman C, Robinson DL, Litvan I (1990) Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 47: 1346–1350.PubMedCrossRefGoogle Scholar
  17. Koller WC, Glatt S, Vetere-Overfield B, Hassanein R (1989) Falls and Parkinson’s disease. Clin Neuropharmacol 12: 98–105.PubMedCrossRefGoogle Scholar
  18. Litvan I, Gomez C, Atack JR, Gillespie M, Kask A, Mouradian MM, Chase TN (1989) Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 26: 404–407.PubMedCrossRefGoogle Scholar
  19. Litvan I, Chase TN (1992) Traditional and expeRImental therapeutic approaches. In: Litvan I, Agid Y (eds) Progressive supranuclear palsy: clinical and research approaches. Oxford University Press, New York, pp 254–269.Google Scholar
  20. Malessa S, Hirsch EC, Cervera P, Javoy-Agid F, Duyckaerts C, Hauw JJ, Agid Y (1991) Progressive supranuclear palsy: loss of choline acetyltransferase-like im-munoreactive neurons in the pontine reticular formation. Neurology 41: 1593–1597.PubMedCrossRefGoogle Scholar
  21. Marchi M, Besana E, Codignola A (1991) Presynaptic cholinergic mechanisms in human cerebral cortex of adult and aged patients. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 92–97.Google Scholar
  22. Pierot L, Desnos C, Blin J, Raisman R, Scherman D, Javoy-Agid F, Ruberg M, Agid Y (1988) D1 and D2-type dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci 86: 291–306.PubMedCrossRefGoogle Scholar
  23. Potter LT (1987) Muscarinic receptors in the cortex and hippocampus in relation to the treatment of Alzheimer’s disease. In: Cohen S, Sokolovsky M (eds) International symposium on muscarinic cholinergic mechanisms. Freud Publishing Ltd, London, pp 294–301.Google Scholar
  24. Rafal RD, Posner MI, Friedman JH, Inhoff A, Bernstein E (1988) Orienting of visual attention in progressive supranuclear palsy. Brain 111: 267–280.PubMedCrossRefGoogle Scholar
  25. Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, Lheureux R, Hauw JJ, Duyckaerts C, Gray F, Morel-Maroger A, Rascol A, Serdaru M, Agid Y (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18: 523–529.PubMedCrossRefGoogle Scholar
  26. Ruberg M, Hirsch E, Javoy-Agid F (1992) Neurochemistry. In: Litvan I, Agid Y (eds) Progressive supranuclear palsy: clinical and research approaches. Oxford University Press, New York, pp 89–109.Google Scholar
  27. Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia, and cerebellum, with vertical gaze and pseudobulbar palsy, nuclear dystonia, and dementia. Arch Neurol 10: 333–359.PubMedCrossRefGoogle Scholar
  28. Thal LJ, Fuld PA, Masur DM, Sharpless NS (1983) Oral physostigmine without lecithin improves memory in Alzheimer’s disease. J Am Geriatr Soc 37: 42–48.Google Scholar
  29. Tagliavini F, Pilleri G, Gemignani F, Lechi A (1983) Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy. Acta Neuropathol 61: 157–160.PubMedCrossRefGoogle Scholar
  30. Weiner DM, Levey AI, Brann MR (1990) Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 87: 7050–7054.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • I. Litvan
    • 1
    • 2
  1. 1.Neuroepidemiology BranchNational Institute of Neurological Disorders and Stroke, National Institutes of HealthBethesdaUSA
  2. 2.Neuroepidemiology BranchNational Institutes of Neurological Disorders and StrokeBethesdaUSA

Personalised recommendations